sta 9090 profile

ID Source	ID
PubMed CID	135564985
CHEMBL ID	2103879
CHEBI ID	177770
SCHEMBL ID	419750
MeSH ID	M0527094

Synonym
HY-15205
888216-25-9
ganetespib
CHEBI:177770
3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1h-1,2,4-triazol-5-one
3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole
D10126
ganetespib (usan)
sta9090
5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-4-(1-methyl-1h-indol-5-yl)-2,4-dihydro-3h- 1,2,4-triazol-3-one
sta-9090
2e8412y946 ,
3h-1,2,4-triazol-3-one, 5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1- methyl-1h-indol-5-yl)-
ganetespib [usan:inn]
sta 9090
unii-2e8412y946
CHEMBL2103879
5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1h-indol-5-yl)-2,4-dihydro-3h-1,2,4-triazol-3-one
ganetespib,sta-9090
BCP0726000115
NCGC00346678-01
5-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-2,4-dihydro-4-(1-methyl-1h-indol-5-yl)-3h-1,2,4-triazol-3-one
triazolone derivative inhibitor of heat shock protein 90
ganetespib [usan]
3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methylindol-5-yl)-5-hydroxy-4h-1,2,4-triazole
ganetespib [inn]
5-(2,4-dihydroxy-5-(propan-2-yl)phenyl)-4-(1-methyl-1h-indol-5-yl)-2,4-dihydro-3h-1,2,4-triazol-3-one
3h-1,2,4-triazol-3-one, 5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1-methyl-1h-indol-5-yl)-
ganetespib [who-dd]
CS-0697
S1159
RVAQIUULWULRNW-UHFFFAOYSA-N
3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(n-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole
4-(5-hydroxy-4-(1-methyl-1h-indol-5-yl)-4h-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol
bdbm50439621
SCHEMBL419750
3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methyl-1h-indol-5-yl)-1h-1,2,4-triazol-5(4h)-one
AC-32480
ganetespib (sta-9090)
3-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1h-indol-5-yl)-4,5-dihydro-1h-1,2,4-triazol-5-one
mfcd22420818
AKOS025396037
AKOS026750420
EX-A250
HMS3654K12
NCGC00346678-04
ganetespib(sta-9090)
SW220253-1
FT-0700397
DB12047
AKOS032947228
BCP22669
sta-9090; sta9090; sta 9090
5-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-4-(1-methyl-1h-indol-5-yl)-2,4-dihydro-3h- 1,2,4-triazol-3-one
AS-35117
AMY16782
(5z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one
SB16526
HMS3673E09
CCG-268213
Q27254612
nsc765435
nsc-777169
nsc-765435
genetespib
nsc777169
DTXSID401025663
Z2235801986
PD087148

Excerpt	Reference
" The most common adverse events were Grade 1 and 2 diarrhea, fatigue, nausea or vomiting."	( A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. Bradley, R; Chen, Y; El-Hariry, I; Goldman, JW; Gordon, GA; Guo, W; Inoue, T; Karol, MD; Raju, RN; Rosen, LS; Teofilivici, F; Vukovic, VM, 2013)

Excerpt	Reference
" Endpoints included safety, pharmacokinetic and pharmacodynamic parameters and preliminary clinical activity."	( A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. Bradley, R; Chen, Y; El-Hariry, I; Goldman, JW; Gordon, GA; Guo, W; Inoue, T; Karol, MD; Raju, RN; Rosen, LS; Teofilivici, F; Vukovic, VM, 2013)
" The pharmacokinetic profile showed that ganetespib exposure in patients with mild hepatic dysfunction is similar to that seen in patients with normal liver function."	( A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Abrams, TA; Blaszkowsky, LS; Chen, J; Goyal, L; Karol, MD; McCleary, NJ; Sheehan, S; Sundaram, E; Wadlow, RC; Wolpin, BM; Zhu, AX, 2015)

Excerpt	Reference
"This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination."	( A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Andric, Z; Bondarenko, I; Ceric, T; Ciuleanu, T; Felip, E; Fennell, D; Goss, G; Hirsh, V; Khuri, F; Komov, D; Ramalingam, S; Rosell, R; Salgia, R; Samarzija, M; Schmid-Bindert, G; Shapiro, G; Sheldon, E; Spicer, J; Teofilovici, F; Vukovic, V; Wehler, T; Zaric, B, 2015)
"Advanced lung adenocarcinoma patients treated with ganetespib in combination with docetaxel had an acceptable safety profile."	( A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Andric, Z; Bondarenko, I; Ceric, T; Ciuleanu, T; Felip, E; Fennell, D; Goss, G; Hirsh, V; Khuri, F; Komov, D; Ramalingam, S; Rosell, R; Salgia, R; Samarzija, M; Schmid-Bindert, G; Shapiro, G; Sheldon, E; Spicer, J; Teofilovici, F; Vukovic, V; Wehler, T; Zaric, B, 2015)

Excerpt	Reference
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)
" Venetoclax (ABT-199) is an orally bioavailable Bcl-2 (B-cell lymphoma 2) inhibitor that stimulates apoptotic signaling pathways in cancer cells."	( The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells. Karademir, D; Özgür, A, 2023)

Excerpt	Reference
"This was a Phase 1 trial in which dogs with spontaneous tumors received STA-1474 under one of three different dosing schemes."	( Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. Barsoum, J; Bear, MD; Foley, KP; Inoue, T; London, CA; McCleese, J; Paalangara, R; Ying, W, 2011)
"3 hours, supporting once-weekly dosing experiments, in which ganetespib produced greater tumor growth inhibition than 17-AAG."	( Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Barsoum, J; Borgman, CL; Carey, CD; Carretero, J; Chen, L; Foley, KP; Inoue, T; Jimenez, JP; Li, D; Li, YC; Meyerson, M; Perera, SA; Rodig, SJ; Sang, J; Shapiro, GI; Shimamura, T; Sinha, P; Wong, KK; Ying, W, 2012)
" In both the prophylactic and therapeutic dosing settings, ganetespib treatment promoted dramatic symptomatic improvements in multiple disease parameters, including suppression of autoantibody production and the preservation of renal tissue integrity and function."	( The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus. Bates, RC; Chu, J; Huang, Q; Inoue, T; Liu, Y; Rao, PE; Shin Ogawa, L; Sonderfan, AJ; Ye, J; Ying, W; Zhou, D, 2015)
" Using conditional mouse models for ADPKD, we performed long-term (10 or 50 wk) dosing experiments that demonstrated HSP90 inhibition caused durable in vivo loss of cilia, controlled cystic growth, and ameliorated symptoms induced by loss of Pkd1 or Pkd2."	( Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). Deneka, AY; Gaponova, A; Golemis, EA; Hensley, HH; Kiseleva, AA; Kopp, MC; Korobeynikov, V; Nikonova, AS; Proia, DA; Seeger-Nukpezah, TN; Serebriiskii, IG; Somlo, S, 2018)
"The combination of the antiangiogenic agent ziv-aflibercept and the heat shock protein 90 inhibitor ganetespib was associated with several serious and unexpected adverse events and was not tolerable on the dosing schedule tested."	( A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. Chen, AP; Do, K; Doroshow, JH; Juwara, L; Kummar, S; Meehan, R; O'Sullivan Coyne, G; Rubinstein, L; Zlott, J, 2018)
"The dose escalation phase of this study was not completed, but the limited data obtained suggest that this combination may be too toxic when administered on this dosing schedule."	( A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. Chen, AP; Do, K; Doroshow, JH; Juwara, L; Kummar, S; Meehan, R; O'Sullivan Coyne, G; Rubinstein, L; Zlott, J, 2018)
" Hsp90 inhibition with ganetespib resulted in modest clinical benefit on two dosing schedules and was associated with significant, although manageable, gastrointestinal toxicity."	( Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Buchbinder, EL; Chen, T; Flaherty, KT; Giobbie-Hurder, A; Hodi, FS; Ibrahim, N; Jacene, HA; Lawrence, DP; Luke, JJ; McDermott, DF; Ott, PA; Shah, S; Sullivan, RJ, 2018)
"05, Panc215, A6L) in a dose-response manner, and the inhibitor in vitro effect on cell growth was evaluated."	( Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures. Eshleman, JR; Gulla, A; Kazlauskas, E; Liang, H; Matulis, D; Petrauskas, V; Strupas, K, 2021)

Class	Description
triazoles	An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
ring assembly	Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	0.0262	0.0052	9.4661	32.9993	AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	13.4504	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.0725	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
G	Vesicular stomatitis virus	Potency	1.6933	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	23.9185	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	0.4430	0.0033	9.1582	39.8107	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	1.6933	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	1.6933	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	1.6933	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Heat shock protein HSP 90-alpha	Homo sapiens (human)	IC50 (µMol)	1.3771	0.0004	0.6950	10.0000	AID1625288; AID1653906; AID1888418; AID767754
Heat shock protein HSP 90-beta	Homo sapiens (human)	IC50 (µMol)	1.8193	0.0010	0.6836	10.0000	AID1625288; AID1888418; AID767753
Endoplasmin	Homo sapiens (human)	IC50 (µMol)	0.0377	0.0220	0.1005	0.3006	AID1653908
Endoplasmin	Canis lupus familiaris (dog)	IC50 (µMol)	0.0100	0.0100	0.1482	0.5780	AID767752
Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)	IC50 (µMol)	0.0444	0.0377	0.4951	1.5860	AID1653907; AID767751
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Heat shock protein HSP 90-alpha	Homo sapiens (human)	Kd	11.7830	0.0003	0.9488	9.8000	AID1342775; AID1668098
Heat shock protein HSP 90-beta	Homo sapiens (human)	Kd	23.5650	0.0003	1.3330	9.8000	AID1668098
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
telomere maintenance via telomerase	Heat shock protein HSP 90-alpha	Homo sapiens (human)
neuron migration	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of protein phosphorylation	Heat shock protein HSP 90-alpha	Homo sapiens (human)
activation of innate immune response	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of defense response to virus by host	Heat shock protein HSP 90-alpha	Homo sapiens (human)
skeletal muscle contraction	Heat shock protein HSP 90-alpha	Homo sapiens (human)
mitochondrial transport	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to unfolded protein	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to heat	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to cold	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to xenobiotic stimulus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to salt stress	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of lamellipodium assembly	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cardiac muscle cell apoptotic process	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of protein ubiquitination	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of protein polymerization	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of interferon-beta production	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of protein localization	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein refolding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to cocaine	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of protein import into nucleus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of apoptotic process	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of protein-containing complex assembly	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein unfolding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to estrogen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein insertion into mitochondrial outer membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of protein catabolic process	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of cell size	Heat shock protein HSP 90-alpha	Homo sapiens (human)
response to antibiotic	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein stabilization	Heat shock protein HSP 90-alpha	Homo sapiens (human)
chaperone-mediated protein complex assembly	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Heat shock protein HSP 90-alpha	Homo sapiens (human)
chaperone-mediated autophagy	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cellular response to virus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levels	Heat shock protein HSP 90-alpha	Homo sapiens (human)
positive regulation of tau-protein kinase activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
telomerase holoenzyme complex assembly	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cellular response to heat	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein folding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
telomere maintenance via telomerase	Heat shock protein HSP 90-beta	Homo sapiens (human)
placenta development	Heat shock protein HSP 90-beta	Homo sapiens (human)
response to unfolded protein	Heat shock protein HSP 90-beta	Homo sapiens (human)
virion attachment to host cell	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathway	Heat shock protein HSP 90-beta	Homo sapiens (human)
regulation of protein ubiquitination	Heat shock protein HSP 90-beta	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of phosphoprotein phosphatase activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
regulation of protein localization	Heat shock protein HSP 90-beta	Homo sapiens (human)
negative regulation of apoptotic process	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of cell differentiation	Heat shock protein HSP 90-beta	Homo sapiens (human)
chaperone-mediated protein complex assembly	Heat shock protein HSP 90-beta	Homo sapiens (human)
regulation of cell cycle	Heat shock protein HSP 90-beta	Homo sapiens (human)
chaperone-mediated protein folding	Heat shock protein HSP 90-beta	Homo sapiens (human)
cellular response to interleukin-4	Heat shock protein HSP 90-beta	Homo sapiens (human)
supramolecular fiber organization	Heat shock protein HSP 90-beta	Homo sapiens (human)
negative regulation of proteasomal protein catabolic process	Heat shock protein HSP 90-beta	Homo sapiens (human)
telomerase holoenzyme complex assembly	Heat shock protein HSP 90-beta	Homo sapiens (human)
positive regulation of protein localization to cell surface	Heat shock protein HSP 90-beta	Homo sapiens (human)
cellular response to heat	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein folding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein stabilization	Heat shock protein HSP 90-beta	Homo sapiens (human)
actin rod assembly	Endoplasmin	Homo sapiens (human)
regulation of phosphoprotein phosphatase activity	Endoplasmin	Homo sapiens (human)
cellular response to ATP	Endoplasmin	Homo sapiens (human)
response to hypoxia	Endoplasmin	Homo sapiens (human)
protein transport	Endoplasmin	Homo sapiens (human)
retrograde protein transport, ER to cytosol	Endoplasmin	Homo sapiens (human)
protein folding in endoplasmic reticulum	Endoplasmin	Homo sapiens (human)
response to endoplasmic reticulum stress	Endoplasmin	Homo sapiens (human)
ERAD pathway	Endoplasmin	Homo sapiens (human)
negative regulation of apoptotic process	Endoplasmin	Homo sapiens (human)
sequestering of calcium ion	Endoplasmin	Homo sapiens (human)
cellular response to manganese ion	Endoplasmin	Homo sapiens (human)
protein folding	Endoplasmin	Homo sapiens (human)
ERAD pathway	Endoplasmin	Canis lupus familiaris (dog)
translational attenuation	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
chaperone-mediated protein folding	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
negative regulation of cellular respiration	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
negative regulation of reactive oxygen species biosynthetic process	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to hydrogen peroxide	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
protein folding	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
UTP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
CTP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
RNA binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
mRNA binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ATP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
GTP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ATP hydrolysis activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
sulfonylurea receptor binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein phosphatase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
MHC class II protein complex binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nitric-oxide synthase regulator activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
TPR domain binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ubiquitin protein ligase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
dATP binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
identical protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein homodimerization activity	Heat shock protein HSP 90-alpha	Homo sapiens (human)
histone deacetylase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
transmembrane transporter binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
tau protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
GTPase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
Rho GDP-dissociation inhibitor binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
DNA polymerase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
scaffold protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
disordered domain specific binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ATP-dependent protein folding chaperone	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein tyrosine kinase binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
unfolded protein binding	Heat shock protein HSP 90-alpha	Homo sapiens (human)
RNA binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
double-stranded RNA binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ATP binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ATP hydrolysis activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein kinase regulator activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
kinase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein kinase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
MHC class II protein complex binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
nitric-oxide synthase regulator activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
TPR domain binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
heat shock protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ubiquitin protein ligase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
peptide binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
identical protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein homodimerization activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
histone deacetylase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ATP-dependent protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein folding chaperone	Heat shock protein HSP 90-beta	Homo sapiens (human)
cadherin binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein dimerization activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
tau protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
DNA polymerase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
disordered domain specific binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
ATP-dependent protein folding chaperone	Heat shock protein HSP 90-beta	Homo sapiens (human)
receptor ligand inhibitor activity	Heat shock protein HSP 90-beta	Homo sapiens (human)
histone methyltransferase binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
unfolded protein binding	Heat shock protein HSP 90-beta	Homo sapiens (human)
RNA binding	Endoplasmin	Homo sapiens (human)
calcium ion binding	Endoplasmin	Homo sapiens (human)
protein binding	Endoplasmin	Homo sapiens (human)
ATP binding	Endoplasmin	Homo sapiens (human)
ATP hydrolysis activity	Endoplasmin	Homo sapiens (human)
protein phosphatase binding	Endoplasmin	Homo sapiens (human)
low-density lipoprotein particle receptor binding	Endoplasmin	Homo sapiens (human)
ATP-dependent protein folding chaperone	Endoplasmin	Homo sapiens (human)
unfolded protein binding	Endoplasmin	Homo sapiens (human)
ATP binding	Endoplasmin	Canis lupus familiaris (dog)
ATP hydrolysis activity	Endoplasmin	Canis lupus familiaris (dog)
ATP-dependent protein folding chaperone	Endoplasmin	Canis lupus familiaris (dog)
RNA binding	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
tumor necrosis factor receptor binding	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
protein binding	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
ATP binding	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
ATP hydrolysis activity	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
protein kinase binding	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
ATP-dependent protein folding chaperone	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
unfolded protein binding	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular region	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nucleus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nucleoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
mitochondrion	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-alpha	Homo sapiens (human)
plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cell surface	Heat shock protein HSP 90-alpha	Homo sapiens (human)
membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
basolateral plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
apical plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
brush border membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
secretory granule lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
melanosome	Heat shock protein HSP 90-alpha	Homo sapiens (human)
neuronal cell body	Heat shock protein HSP 90-alpha	Homo sapiens (human)
lysosomal lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
dendritic growth cone	Heat shock protein HSP 90-alpha	Homo sapiens (human)
axonal growth cone	Heat shock protein HSP 90-alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
collagen-containing extracellular matrix	Heat shock protein HSP 90-alpha	Homo sapiens (human)
extracellular exosome	Heat shock protein HSP 90-alpha	Homo sapiens (human)
endocytic vesicle lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
sperm mitochondrial sheath	Heat shock protein HSP 90-alpha	Homo sapiens (human)
sperm plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
ficolin-1-rich granule lumen	Heat shock protein HSP 90-alpha	Homo sapiens (human)
protein-containing complex	Heat shock protein HSP 90-alpha	Homo sapiens (human)
plasma membrane	Heat shock protein HSP 90-alpha	Homo sapiens (human)
neuronal cell body	Heat shock protein HSP 90-alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-alpha	Homo sapiens (human)
myelin sheath	Heat shock protein HSP 90-alpha	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-alpha	Homo sapiens (human)
nucleus	Heat shock protein HSP 90-alpha	Homo sapiens (human)
COP9 signalosome	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein folding chaperone complex	Heat shock protein HSP 90-beta	Homo sapiens (human)
extracellular region	Heat shock protein HSP 90-beta	Homo sapiens (human)
nucleus	Heat shock protein HSP 90-beta	Homo sapiens (human)
nucleoplasm	Heat shock protein HSP 90-beta	Homo sapiens (human)
cytoplasm	Heat shock protein HSP 90-beta	Homo sapiens (human)
mitochondrion	Heat shock protein HSP 90-beta	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-beta	Homo sapiens (human)
cell surface	Heat shock protein HSP 90-beta	Homo sapiens (human)
membrane	Heat shock protein HSP 90-beta	Homo sapiens (human)
secretory granule lumen	Heat shock protein HSP 90-beta	Homo sapiens (human)
melanosome	Heat shock protein HSP 90-beta	Homo sapiens (human)
neuronal cell body	Heat shock protein HSP 90-beta	Homo sapiens (human)
dendritic growth cone	Heat shock protein HSP 90-beta	Homo sapiens (human)
axonal growth cone	Heat shock protein HSP 90-beta	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-beta	Homo sapiens (human)
extracellular exosome	Heat shock protein HSP 90-beta	Homo sapiens (human)
dynein axonemal particle	Heat shock protein HSP 90-beta	Homo sapiens (human)
ficolin-1-rich granule lumen	Heat shock protein HSP 90-beta	Homo sapiens (human)
protein-containing complex	Heat shock protein HSP 90-beta	Homo sapiens (human)
aryl hydrocarbon receptor complex	Heat shock protein HSP 90-beta	Homo sapiens (human)
HSP90-CDC37 chaperone complex	Heat shock protein HSP 90-beta	Homo sapiens (human)
perinuclear region of cytoplasm	Heat shock protein HSP 90-beta	Homo sapiens (human)
plasma membrane	Heat shock protein HSP 90-beta	Homo sapiens (human)
cytosol	Heat shock protein HSP 90-beta	Homo sapiens (human)
extracellular region	Endoplasmin	Homo sapiens (human)
nucleus	Endoplasmin	Homo sapiens (human)
endoplasmic reticulum	Endoplasmin	Homo sapiens (human)
endoplasmic reticulum lumen	Endoplasmin	Homo sapiens (human)
endoplasmic reticulum membrane	Endoplasmin	Homo sapiens (human)
smooth endoplasmic reticulum	Endoplasmin	Homo sapiens (human)
cytosol	Endoplasmin	Homo sapiens (human)
focal adhesion	Endoplasmin	Homo sapiens (human)
membrane	Endoplasmin	Homo sapiens (human)
midbody	Endoplasmin	Homo sapiens (human)
sarcoplasmic reticulum lumen	Endoplasmin	Homo sapiens (human)
melanosome	Endoplasmin	Homo sapiens (human)
perinuclear region of cytoplasm	Endoplasmin	Homo sapiens (human)
collagen-containing extracellular matrix	Endoplasmin	Homo sapiens (human)
extracellular exosome	Endoplasmin	Homo sapiens (human)
endocytic vesicle lumen	Endoplasmin	Homo sapiens (human)
sperm plasma membrane	Endoplasmin	Homo sapiens (human)
protein-containing complex	Endoplasmin	Homo sapiens (human)
endoplasmic reticulum chaperone complex	Endoplasmin	Homo sapiens (human)
endoplasmic reticulum	Endoplasmin	Homo sapiens (human)
perinuclear region of cytoplasm	Endoplasmin	Homo sapiens (human)
sarcoplasmic reticulum lumen	Endoplasmin	Canis lupus familiaris (dog)
melanosome	Endoplasmin	Canis lupus familiaris (dog)
nucleoplasm	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
mitochondrion	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
mitochondrial intermembrane space	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
membrane	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
cell periphery	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Heat shock protein 75 kDa, mitochondrial	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (103)

Assay ID	Title	Year	Journal	Article
AID1653910	Ratio of IC50 for GRP94 (unknown origin) to IC50 for recombinant HSP90alpha (unknown origin) incubated for 24 hrs in presence of 1-FITC3 probe	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.
AID1653907	Inhibition of TRAP1 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.
AID1322395	Antiangiogenic activity in HRMEC assessed as inhibition of VEGF-induced cell migration under hypoxic condition at 100 nM after 4 hrs by hematoxylin and eosin staining-based phase-contrast microscopy	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.
AID1888407	Synergistic antifungal activity against azole-resistant Candida albicans 0304103 assessed as fractional inhibitory concentration index in presence of fluconazole incubated for 48 hrs by CLSI based checkerboard microdilution assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1653908	Inhibition of GRP94 (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.
AID1648054	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability up to 3 uM measured after 24 hrs by MTT assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.
AID1625287	Inhibition of EML4-ALK variant 1 (unknown origin) expressed in BA/F3 cells assessed as decrease in cell viability after 24 hrs by CellTiter-Glo assay	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1625296	Ratio of crizotinib IC50 to compound IC50 for human NB39 cells	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1888419	Inhibition of fungal HSP90 incubated for 6 hrs in presence of FITC-Geldanamycin by fluorescence polarization analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1653912	Antiproliferative activity against human PC3 cells by MTT assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.
AID1625286	Cytotoxicity against human NB39 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1322394	Antiangiogenic activity in HRMEC assessed as inhibition of VEGF-induced cell proliferation under hypoxic condition by measuring [3H]-thymidine incorporation at 100 nM preincubated for 24 hrs followed by [3H]-thymidine addition measured after 6 hrs by liqu	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.
AID1625301	Cytotoxicity against human A375 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1888426	Toxicity in ICR mouse infected with azole-resistant Candida albicans 0304103 assessed as reduction in survival time at 10 mg/kg, ip administered once daily for 5 days	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1625295	Potency index, ratio of crizotinib IC50 to compound IC50 for inhibition of E13;A20 EML4-ALK variant (unknown origin) expressed in human NCI-H3122 cells	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1888416	Inhibition of fungal filamentation in azole-resistant Candida albicans 0304103 assessed as reduction in yeast-hypha transition at 64 ug/ml by inverted microscopic analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1648056	Cytotoxicity against human HeLa cells assessed as reduction in cell viability up to 3 uM measured after 24 hrs by MTT assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.
AID767754	Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from HSP90alpha (unknown origin) after 24 hrs by fluorescence polarization assay	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.
AID767752	Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from dog Grp94 after 24 hrs by fluorescence polarization assay	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.
AID1648057	Cytotoxicity against human LN229 cells assessed as reduction in cell viability up to 3 uM measured after 24 hrs by MTT assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.
AID1888404	Antifungal activity against azole-resistant Candida albicans 0304103 assessed as fungal growth inhibition incubated for 48 hrs by CLSI based checkerboard microdilution assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1625303	Potency index, ratio of selumetinib IC50 to compound IC50 for human A375 cells	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1888417	Inhibition of fungal filamentation in azole-resistant Candida albicans 0304103 assessed as reduction in yeast-hypha transition at 64 ug/ml in presence of fluconazole by inverted microscopic analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1653911	Antiproliferative activity against human HeLa cells by MTT assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.
AID767751	Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from recombinant human Trap-1 after 24 hrs by fluorescence polarization assay	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.
AID1170902	Increase in oxygen consumption rate/extracellular acidification rate ratio in human NCI-H1299 cells at incubated for 12 hrs	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.
AID1888405	Synergistic antifungal activity against azole-resistant Candida albicans 0304103 assessed as fractional inhibitory concentration in presence of fluconazole incubated for 48 hrs by CLSI based checkerboard microdilution assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1648053	Cytotoxicity against human PC3 cells assessed as reduction in cell viability up to 3 uM measured after 24 hrs by MTT assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.
AID1888418	Inhibition of human HSP90	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1760003	Cytotoxicity against mouse 661W cells by MTT based vision related toxicity assay	2021	European journal of medicinal chemistry, Jul-05, Volume: 219	Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
AID1625292	Inhibition of E6a/b;A20 EML4-ALK (unknown origin) expressed in human NCI-H2228 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1625304	Antitumor activity against vemurafenib-resistant human A375 cells xenografted in mouse assessed as tumor growth inhibition at 150 mg/kg, iv dosed as weekly treatment in presence of selumetinib	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1668095	Binding affinity to HSP90 (unknown origin) assessed as Stern-Volmer quenching constant by Stern-Volmer plot analysis	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
AID1625302	Potency index, ratio of vemurafenib IC50 to compound IC50 for human A375 cells	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1668096	Binding affinity to HSP90 (unknown origin) assessed as quenching constant by Stern-Volmer plot analysis	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
AID1741079	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay	2020	European journal of medicinal chemistry, Oct-01, Volume: 203	Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.
AID1625293	Potency index, ratio of crizotinib IC50 to compound IC50 for human NCI-H2228 cells	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1888406	Synergistic antifungal activity against azole-resistant Candida albicans 0304103 assessed as fractional inhibitory concentration incubated for 48 hrs by CLSI based checkerboard microdilution assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1409632	Induction of heat shock response in GFP-tagged human 293T cells after overnight incubation by luciferase reporter gene based luminometric method relative to control	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Withaferin A and Withanolide D Analogues with Dual Heat-Shock-Inducing and Cytotoxic Activities: Semisynthesis and Biological Evaluation.
AID767753	Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from recombinant HSP90beta (unknown origin) after 24 hrs by fluorescence polarization assay	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.
AID1668084	Binding affinity to HSP90 (unknown origin) by Line weaver-Burk plot analysis	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
AID1409630	Cytotoxicity against human CHP100 cells assessed as reduction in cell viability after 24 hrs by resazurin dye based Alamar blue assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Withaferin A and Withanolide D Analogues with Dual Heat-Shock-Inducing and Cytotoxic Activities: Semisynthesis and Biological Evaluation.
AID1625294	Inhibition of E13;A20 EML4-ALK variant (unknown origin) expressed in human NCI-H3122 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1668098	Binding affinity to HSP90 (unknown origin) by fluorescence quenching method	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
AID1888410	Cytotoxicity against human HaCaT cells assessed as inhibition of cell growth	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
AID1409631	Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by resazurin dye based Alamar blue assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Withaferin A and Withanolide D Analogues with Dual Heat-Shock-Inducing and Cytotoxic Activities: Semisynthesis and Biological Evaluation.
AID1625288	Inhibition of Hsp90 in human MG63 cells	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
AID1653909	Ratio of IC50 for TRAP1 (unknown origin) to IC50 for recombinant HSP90alpha (unknown origin) incubated for 24 hrs in presence of 1-FITC3 probe	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.
AID1653906	Inhibition of recombinant HSP90alpha (unknown origin) incubated for 24 hrs in presence of 1-FITC3 probe by fluorescence polarization assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (0.75)	29.6817
2010's	106 (79.70)	24.3611
2020's	26 (19.55)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	13 (9.77%)	5.53%
Reviews	11 (8.27%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	109 (81.95%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	3.18	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycine [no description available]	3.18	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.31	1	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.31	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	2.1	1	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.41	1	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.82	3	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
imatinib [no description available]	3.23	1	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.41	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
tegafur [no description available]	2.25	1	0	organohalogen compound; pyrimidines
pentylenetetrazole Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.	2.21	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.08	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.15	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
cytarabine [no description available]	2.11	1	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
acrylic acid acrylic acid: RN given refers to parent cpd. acrylic acid : A alpha,beta-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.	2.15	1	0	alpha,beta-unsaturated monocarboxylic acid	metabolite
dichloroacetic acid [no description available]	2.1	1	0	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.08	1	0	pyrrole; secondary amine
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.08	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	3.18	1	0	indazole
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	5.02	6	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazolidines Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.	2.11	1	0	thiazolidine
deoxycytidine [no description available]	2.1	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
lutetium Lutetium: An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.	2.21	1	0	d-block element atom; lanthanoid atom
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	2.31	1	0	elemental platinum; nickel group element atom; platinum group metal atom
cerium Cerium: An element of the rare earth family of metals. It has the atomic symbol Ce, atomic number 58, and atomic weight 140.12. Cerium is a malleable metal used in industrial applications.	2.61	2	0	f-block element atom; lanthanoid atom
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.11	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	3.02	4	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.05	1	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
irinotecan [no description available]	2.11	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	2.1	1	0	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.21	1	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
5-methylcytosine 5-Methylcytosine: A methylated nucleotide base found in eukaryotic DNA. In ANIMALS, the DNA METHYLATION of CYTOSINE to form 5-methylcytosine is found primarily in the palindromic sequence CpG. In PLANTS, the methylated sequence is CpNpGp, where N can be any base.. 5-methylcytosine : A pyrimidine that is a derivative of cytosine, having a methyl group at the 5-position.	2.15	1	0	methylcytosine; pyrimidines	human metabolite
rhodamine 123 [no description available]	2.31	1	0	organic chloride salt; xanthene dye	fluorochrome
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	14.84	112	13	1,2,3-triazole
ceric oxide ceric oxide: RN given refers to cpd with MF CeO2. ceric oxide : A metal oxide with formula CeO2. It is used for polishing glass, in coatings for infra-red filters to prevent reflection, and as an oxidant and catalyst in organic synthesis.	2.61	2	0	cerium molecular entity; metal oxide
triphenylmethylphosphonium triphenylmethylphosphonium: RN given refers to parent cpd	2.25	1	0
n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.	2.21	1	0	methyladenosine
deguelin deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.	2.13	1	0	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite
tanshinone tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent	2.17	1	0	abietane diterpenoid	anticoronaviral agent
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	5.14	5	2	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
withanolide d withanolide D: structure. withanolide D : A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 22 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Tubocapsicum anomalum and Withania somnifera, it exhibits cytotoxic activity.	2.17	1	0	20-hydroxy steroid; 4-hydroxy steroid; delta-lactone; enone; epoxy steroid; ergostanoid; secondary alcohol; tertiary alcohol; withanolide	antineoplastic agent
erlotinib hydrochloride [no description available]	2.08	1	0	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
sorafenib [no description available]	2.6	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.11	1	0
withaferin a withaferin A: an antiestrogen and phytogenic antineoplastic agent isolated from leaves of Withania somnifera Dun.; structure. withaferin A : A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 27 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Physalis longifolia, it exhibits cytotoxic activity.	2.17	1	0	27-hydroxy steroid; 4-hydroxy steroid; delta-lactone; enone; epoxy steroid; ergostanoid; primary alcohol; secondary alcohol; withanolide	antineoplastic agent; apoptosis inducer
carboplatin [no description available]	2.54	2	0
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.17	1	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
zn(ii)-phthalocyanine [no description available]	2.17	1	0	metallophthalocyanine; zinc tetrapyrrole	fluorochrome
tamoxifen [no description available]	2.11	1	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
geldanamycin [no description available]	3.93	3	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: structure in first source. alvespimycin : A 19-membered macrocyle that is geldanamycin in which the methoxy group attached to the benzoquinone moiety has been replaced by a 2-(N,N-dimethylamino)ethylamino group.	5.32	6	0	1,4-benzoquinones; ansamycin; carbamate ester; secondary amino compound; tertiary amino compound	Hsp90 inhibitor
su 11248 [no description available]	2.08	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
geldanamycin [no description available]	3.89	3	0
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	3.59	2	0	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
16-(2'-o-glucopyranosylglucopyranosyloxy)hexadecanoic acid 1',4''-lactone 6',6''-diacetate 16-(2'-O-glucopyranosylglucopyranosyloxy)hexadecanoic acid 1',4''-lactone 6',6''-diacetate: from Torulopsis apicola; structure given in first source	2.31	1	0
tanespimycin CP 127374: analog of herbimycin A	6.51	17	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
taxane taxane: produced by Taxomyces andreanae	2.15	1	0	diterpene; terpenoid fundamental parent
9h-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-n-(1-methylethyl)- 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-: an epichaperome (purine-scaffold) inhibitor; structure in first source	3.24	5	0
azd 6244 AZD 6244: a MEK inhibitor	2.49	2	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	6	4	1	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
at 13387 (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone: structure in first source. onalespib : A member of the class of isoindoles that is isoindole in which the amino group has been acylated by a 2,4-dihydroxy-5-isopropylbenzoyl group and in which position 5 of the isoidole moiety has been substituted by a (4-methylpiperazin-1-yl)methyl group. A second-generation Hsp90 inhibitor.	4.86	5	0	benzamides; isoindoles; N-alkylpiperazine; resorcinols; tertiary carboxamide	antineoplastic agent; Hsp90 inhibitor
veliparib [no description available]	2.15	1	0	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.07	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
cnf 2024 [no description available]	3.06	4	0	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
olaparib [no description available]	2.25	1	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
snx 2112 SNX 2112: an orally available small molecule Hsp90 inhibitor; structure in first source	3.04	4	0
tak 733 [no description available]	2.1	1	0
ver 155008 VER 155008: structure in first source	2.11	1	0	purine nucleoside
plx4032 [no description available]	3.61	2	0	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
debio 0932 CUDC 305: an Hsp90 inhibitor with antineoplastic activity; structure in first source	2.52	2	0
glycolipids [no description available]	2.31	1	0
pf 04929113 [no description available]	3.18	1	0
piperidines Piperidines: A family of hexahydropyridines.	2.1	1	0
dabrafenib [no description available]	2.08	1	0	1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide	anticoronaviral agent; antineoplastic agent; B-Raf inhibitor
alectinib [no description available]	2.1	1	0	aromatic ketone; morpholines; nitrile; organic heterotetracyclic compound; piperidines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	2.6	1	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea infigratinib: structure in first source. BGJ-398 : A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor.	2.21	1	0	aminopyrimidine; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; phenylureas	antineoplastic agent; fibroblast growth factor receptor antagonist
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	3.17	1	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	2.1	1	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	3.17	1	0
ceritinib ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.	2.08	1	0	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2h-chromen-6-yl)ethanone 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethanone: an Hsp90 inhibitor; structure in first source	2.13	1	0
transforming growth factor alpha Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.	2.1	1	0
angiogenin angiogenin: human tumor protein which stimulates growth of blood vessels; contains 123 amino acids; member of the pancreatic ribonuclease superfamily; MW 14,400	3	1	0
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.15	1	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	2.17	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	2.08	1	0
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	4.18	4	0	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
defibrotide defibrotide: Single-stranded polydeoxyribonucleotide extracted from mammalian organs and used in the treatment of HEPATIC VENO-OCCLUSIVE DISEASE in patients with kidney or lung abnormalities following HEMATOPOIETIC STEM CELL TRANSPLANTATION	3.57	2	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.1	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Angiogenesis, Pathologic [description not available]	0	2.52	2	0
Ewing Sarcoma [description not available]	0	2.57	2	0
Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.	0	2.57	2	0
Benign Neoplasms [description not available]	0	9.34	13	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	11.34	13	2
Carcinoma, Non-Small Cell Lung [description not available]	0	8.11	19	3
Cancer of Lung [description not available]	0	8.69	25	3
Colorectal Cancer [description not available]	0	5.66	6	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	1	10.11	19	3
Lung Neoplasms Tumors or cancer of the LUNG.	1	10.69	25	3
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	5.66	6	1
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	5.32	11	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Anoxemia [description not available]	0	2.6	1	0
Hepatocellular Carcinoma [description not available]	0	4	2	1
Cancer of Liver [description not available]	0	4.25	3	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	2.6	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	1	6	2	1
Liver Neoplasms Tumors or cancer of the LIVER.	0	4.25	3	1
Cancer of Cervix [description not available]	0	2.6	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	2.6	1	0
Experimental Hepatoma [description not available]	0	2.25	1	0
Cancer of Esophagus [description not available]	0	4.55	1	1
Cancer of Stomach [description not available]	0	5.15	3	1
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	1	6.55	1	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	1	7.15	3	1
Epithelial Ovarian Cancer [description not available]	0	2.31	1	0
Cancer of Ovary [description not available]	0	2.84	3	0
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	0	2.31	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1	4.84	3	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	0	2.31	1	0
Cancer of Mouth [description not available]	0	2.31	1	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	0	2.31	1	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	0	2.31	1	0
Breast Cancer [description not available]	0	4.77	6	1
Breast Neoplasms Tumors or cancer of the human BREAST.	1	6.77	6	1
Osteogenic Sarcoma [description not available]	0	2.31	1	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	2.31	1	0
Cancer of Pancreas [description not available]	0	4.8	6	1
Carcinoma, Ductal, Pancreatic [description not available]	0	4.3	3	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	4.8	6	1
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	0	4.3	3	1
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	0	2.31	1	0
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	0	2.31	1	0
Cancer of the Thyroid [description not available]	0	2.15	1	0
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	0	2.15	1	0
Cancer of Colon [description not available]	0	2.15	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	1	4.15	1	0
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	0	2.15	1	0
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	0	2.15	1	0
Malignant Melanoma [description not available]	0	4.42	4	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1	6.42	4	1
Malignant Mesothelioma [description not available]	0	2.17	1	0
Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)	1	4.17	1	0
ADPKD [description not available]	0	2.53	2	0
Polycystic Kidney, Autosomal Dominant Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.	0	2.53	2	0
Experimental Mammary Neoplasms [description not available]	0	2.57	2	0
Sarcoma, Epithelioid [description not available]	0	4.48	1	1
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	4.48	1	1
Cholangiocellular Carcinoma [description not available]	0	2.21	1	0
Bile Duct Cancer [description not available]	0	2.21	1	0
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	0	2.21	1	0
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	0	2.21	1	0
Mast-Cell Leukemia [description not available]	0	3.87	2	1
Leukemia, Mast-Cell A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of	0	3.87	2	1
Cancer of Skin [description not available]	0	4.21	3	1
Skin Neoplasms Tumors or cancer of the SKIN.	0	4.21	3	1
Uveal Neoplasms Tumors or cancer of the UVEA.	0	3.56	1	1
Innate Inflammatory Response [description not available]	0	2.82	3	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.82	3	0
Absence Seizure Disorder [description not available]	0	2.21	1	0
Epilepsy, Absence A seizure disorder usually occurring in childhood characterized by rhythmic electrical brain discharges of generalized onset. Clinical features include a sudden cessation of ongoing activity usually without loss of postural tone. Rhythmic blinking of the eyelids or lip smacking frequently accompanies the SEIZURES. The usual duration is 5-10 seconds, and multiple episodes may occur daily. Juvenile absence epilepsy is characterized by the juvenile onset of absence seizures and an increased incidence of myoclonus and tonic-clonic seizures. (Menkes, Textbook of Child Neurology, 5th ed, p736)	0	2.21	1	0
Androgen-Independent Prostatic Cancer [description not available]	0	3.94	2	1
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	0	3.94	2	1
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	0	4.28	6	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	1	6.28	6	0
Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.	0	2.21	1	0
Adrenal Cancer [description not available]	0	2.08	1	0
Metastase [description not available]	0	5.65	6	3
Pheochromocytoma, Extra-Adrenal [description not available]	0	2.08	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	5.65	6	3
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	0	2.08	1	0
Adenocarcinoma, Basal Cell [description not available]	0	5.31	4	1
Cancer of Rectum [description not available]	0	3	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	5.31	4	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	1	5	1	0
Lung Adenocarcinoma [description not available]	0	2.5	2	0
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	1	4.5	2	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	2.52	2	0
Carcinoma, Small Cell Lung [description not available]	0	3.71	3	0
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	1	5.71	3	0
Invasiveness, Neoplasm [description not available]	0	2.51	2	0
Atherogenesis [description not available]	0	2.1	1	0
Atheroma [description not available]	0	2.1	1	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	0	2.1	1	0
Bladder Cancer [description not available]	0	2.81	3	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	0	2.81	3	0
Carcinoma, Epidermoid [description not available]	0	2.1	1	0
Cancer of Oropharnyx [description not available]	0	2.1	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	2.1	1	0
Oropharyngeal Neoplasms Tumors or cancer of the OROPHARYNX.	0	2.1	1	0
Liver Dysfunction [description not available]	0	3.5	1	1
Liver Diseases Pathological processes of the LIVER.	0	3.5	1	1
Blast Phase [description not available]	0	2.11	1	0
Acute Myelogenous Leukemia [description not available]	0	2.11	1	0
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	0	2.11	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1	4.11	1	0
Disease Exacerbation [description not available]	0	2.11	1	0
Libman-Sacks Disease [description not available]	0	2.11	1	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	0	2.11	1	0
Germinoblastoma [description not available]	0	2.53	2	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	0	2.53	2	0
EBV Infections [description not available]	0	2.15	1	0
Epstein-Barr Virus Infections Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).	0	2.15	1	0
Genetic Predisposition [description not available]	0	2.15	1	0
Angiosarcoma [description not available]	0	2.15	1	0
Hemangiosarcoma A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)	1	4.15	1	0
Lymph Node Metastasis [description not available]	0	3.56	1	1
Benign Mastocytoma [description not available]	0	2.04	1	0
Canine Diseases [description not available]	0	2.04	1	0
Granulocytic Leukemia [description not available]	0	2.05	1	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	0	2.05	1	0
Experimental Neoplasms [description not available]	0	2.48	2	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.07	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.07	1	0
Cancer of Prostate [description not available]	0	2.08	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	1	4.08	1	0

sta 9090

Cross-References

Synonyms (69)

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (2)

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (112)

Molecular Functions (59)

Ceullar Components (56)

Bioassays (103)

Research

Studies (133)

Study Types

sta 9090

Cross-References

Synonyms (69)

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (2)

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (112)

Molecular Functions (59)

Ceullar Components (56)

Bioassays (103)

Research

Studies (133)

Study Types

Related Drugs (90)

Related Conditions (128)